Skip to content

Trevi Therapeutics, Inc.

TRVI· NasdaqCore metricsCIK 1563880

Pharmaceutical preparations551 peers

Last sale
Nov 6, 2026 · +11.94%
Market cap
$2.04B
142.56M shares
Filings
540
—
—
—
-$21.45M
Q3 2026N/M FY25 yoy
-$24.49M
Q3 2026N/M FY25 yoy
-$54.06M
Q3 2026derivedN/M FY25 yoy
-$0.13
Q3 2026N/M FY25 yoy
$27.85M
Q3 2026−44.5% FY25 yoy
$2.04B
—
—
6.8×
-2.06%
—

FY2025 figures · derived

Price

$14.34+34.77%+$3.70past year
Nov 6, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Research And Development

$33.48MFY 2025
$39.38M0FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$33,478,000reported
FY 20242024-12-31$39,377,000reported
FY 20232023-12-31$23,683,000reported
FY 20222022-12-31$19,834,000reported
FY 20212021-12-31$22,984,000reported
FY 20202020-12-31$22,328,000reported
FY 20192019-12-31$19,339,000reported
FY 20182018-12-31$14,072,000reported

Pharmaceutical preparations

Trevi Therapeutics, Inc. is the 95th largest of the 552 covered companies the SEC files under this code, by market cap. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Trevi Therapeutics, Inc. · CIK 1563880 · Engraved from SEC EDGAR